Side-by-side comparison of AI visibility scores, market position, and capabilities
US AI clinical trial design and systematic review automation extracting data from papers and figures at 15x industry speed for two top-10 pharma partners; competing with Elsevier Reaxys for biopharma evidence synthesis that reduces study times from months to weeks.
Delineate is a United States-based AI clinical trial design and biomedical data extraction company — providing pharmaceutical companies, academic research teams, and contract research organizations (CROs) with AI-powered systematic review automation that accelerates the data extraction and evidence synthesis workflows critical for designing better, faster clinical trials in the $10 billion clinical trial design and data services market. Partnered with two top-10 global pharmaceutical companies, Delineate has performed some of the largest systematic-review studies ever conducted in drug development, delivering 15x more processed studies than industry standard timelines and reducing certain study completion times from months to weeks through AI models that extract and analyze data from biopharma research papers, patents, and regulatory documents at scale.
AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.
Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.